Out-Of-Favor Drug Shows Promise In Restenosis

3 September 1997

Probucol, an old lipid-lowering agent taken off the market by HoechstMarion Roussel in 1995, has been found to cut the rate of restenosis after angioplasty, according to a study reported in the New England Journal of Medicine (August 7). However, the new study also found that taking antioxidant multivitamins, either alone or in combination with the drug, provided no benefit in this indication.

Probucol is no longer on the market in Europe and the USA, having been withdrawn in 1995 in advance of a US Food and Drug Administration advisory committee meeting to discuss the product's supposed lack of efficacy. The drug was originally marketed under the trade name Lorelco, but was approved when there was less understanding of the pathology of hypercholesterolemia. In addition to its lowering effects on low-density lipoprotein cholesterol, probucol also lowers high-density lipoprotein cholesterol, and HDL particles are now known to be protective against coronary artery disease.

The product was never a major earner for HMR; in 1994 probucol's sales were just under $14 million. However, the drug is still on the market in Japan, where antioxidant treatment as a concept is more widely regarded. Japanese physicians use probucol as a treatment for stomach cancer, but four small (uncontrolled) clinical studies have been published in Japan which support probucol's role post-angioplasty.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight